Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 153

Sort by

Sort Order Select

Journal Articles

Outcome of Patients with Newly-Diagnosed Therapy-Related AML (t-AML) and AML with Myelodysplasia-Related Changes (AML-MRC) Treated with Liposomal Daunorubicin and Cytarabine (CPX-351) at an Academic Community-Based Health System

John Khoury, MD, Nwabundo Anusim, MD, David Macari, MD, Angela Duenn, PharmD, Ishmael Jaiyesimi, DO, MS

Blood (2019) 134 (Supplement_1): 5117.

https://doi.org/10.1182/blood-2019-130776

Published: 2019

Journal Articles

A Multicenter Nonrandom Clinical Study Using Induction Regimen of FLAG-IDA or Dae in Treatment of 101 Children with Newly Diagnosed CBF-AML in South of China: Clinical Responses and the Midterm Report of Survival

Xiaoqin Feng, Jian Li, MD, Chunfu Li, MD, Mincui Zheng, Honggui Xu, Yingyi He, MD& PhD, Changgang Li, MD, Hong Wen, Xiangling He, Lihua Yang, MD PhD

Blood (2019) 134 (Supplement_1): 3857.

https://doi.org/10.1182/blood-2019-126863

Published: 2019

Journal Articles

Phase 3 Exploratory Analysis of Outcomes in Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Received Consolidation with CPX-351 Versus Conventional Chemotherapy

Jonathan E. Kolitz, MD, Daniel H. Ryan, MD, Laura F. Newell, MD, Stephen A. Strickland, MD, Donna E. Hogge, MD PhD, Scott R. Solomon, MD, Gary J. Schiller, MD, Robert J. Ryan, MS, Stefan Faderl, MD, Jorge E. Cortes, MD

Blood (2019) 134 (Supplement_1): 3856.

https://doi.org/10.1182/blood-2019-124553

Published: 2019

Journal Articles

Outcomes in Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory Analysis

Daniel H. Ryan, MD, Laura F. Newell, MD, Ellen K. Ritchie, MD, Stephen A. Strickland, MD, Donna E. Hogge, MD PhD, Scott R. Solomon, MD, Richard M. Stone, MD, Gary J. Schiller, MD, Matthew J. Wieduwilt, MD PhD, Robert J. Ryan, MS, Stefan Faderl, MD, Jorge E. Cortes, MD

Blood (2019) 134 (Supplement_1): 3842.

https://doi.org/10.1182/blood-2019-124516

Published: 2019

Journal Articles

Acute Myeloid Leukemia with Myelodisplasia-Related Changes (AML-MRC) Defined Only By Morphological Findings May Not Represent a Poor Prognosis AML

Blood (2019) 134 (Supplement_1): 2612.

https://doi.org/10.1182/blood-2019-129153

Published: 2019

Journal Articles

Molecular Classification of AML-MRC Reveals a Distinct Profile and Identifies MRC-like Patients with Poor Overall Survival

Constance Baer, PhD, Wencke Walter, PhD, Anna Stengel, PhD, Stephan Hutter, PhD, Manja Meggendorfer, PhD, Wolfgang Kern, MD, Claudia Haferlach, MD, Torsten Haferlach, MD

Blood (2019) 134 (Supplement_1): 2735.

https://doi.org/10.1182/blood-2019-128234

Published: 2019

Journal Articles

Outcomes of Patients with Acute Myeloid Leukemia (AML) with Myelodysplasia Related Changes (AML-MRC) Are Dependent on Diagnostic Criteria and Therapy

Guillermo Montalban Bravo, MD, Rashmi Kanagal-Shamanna, MD, Koji Sasaki, MD, Farhad Ravandi, MD, Jorge E. Cortes, MD, Naval G. Daver, MD, Koichi Takahashi, MD, Courtney D. DiNardo, MDMSc, Elias Jabbour, MD, Gautam M. Borthakur, MD, Kiran Naqvi, MDMPH, Marina Y Konopleva, MD PhD, Sherry A. Pierce, BSN, BA, Carlos E. Bueso-Ramos, MD PhD, Keyur P. Patel, MBBS, PhD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD, Tapan M. Kadia, MD

Blood (2019) 134 (Supplement_1): 1312.

https://doi.org/10.1182/blood-2019-131998

Published: 2019

Journal Articles

CPX-351 Induces Deep Response and Suppress the Impact of Poor Prognosis Mutations ( TP53, ASXL1, RUNX1 and EVI1 ) Defined By ELN-2017 in t-AML and MRC AML: A Report from a Multicentric French Cohort

Blood (2019) 134 (Supplement_1): 1355.

https://doi.org/10.1182/blood-2019-125623

Published: 2019

Journal Articles

Outcomes of Relapsed/Refractory Patients with IDH1/2 Mutated AML Treated with Non-Targeted Therapy: Results from the NCRI AML Trials

Robert K. Hills, MA,DPhil,MSc, Rosemary Gale, PhD, David C. Linch, Brian J.P Huntly, Elli Papaemmanuil, PhD, Paresh Vyas, Alan K. Burnett, MD, Nigel H. Russell

Blood (2018) 132 (Supplement 1): 664.

https://doi.org/10.1182/blood-2018-99-116482

Published: 2018

Journal Articles

Comparison of Induction Strategies and Responses for Acute Myeloid Leukemia Patients after Resistance to Hypomethylating Agents for Antecedent Myeloid Malignancy

Chetasi Talati, MD, Aaron D Goldberg, MDPhD, Amanda Przespolewski, DO, Onyee Chan, MD, Najla Al Ali, M.Sc, Christopher Famulare, MS, David A Sallman, MD, Eric Padron, MD, Andrew Kuykendall, MD, Alan F. List, MD, Jeffrey E. Lancet, MD, Eunice S. Wang, MD, Martin S. Tallman, MD, Rami S. Komrokji, MD, Kendra L. Sweet, MD

Blood (2018) 132 (Supplement 1): 665.

https://doi.org/10.1182/blood-2018-99-119879

Published: 2018

Journal Articles

Impact of Genetic Profile on Clinical Outcomes in Adults ≥60 with AML: The Princess Margaret Cancer Centre Experience

Georgina S Daher-Reyes, MD, Caroline J McNamara, MBBS, Manjula Maganti, MSc, Tracy L. Stockley, PhD FCCMG, FACMG, Jose Mario Capo-Chichi, PhD FACMG, Reem Abdulrahman Alkharras, Andrea Arruda, Jaime Claudio, Steven M Chan, MD PhD, Aaron D Schimmer, MD PhD, Mark D. Minden, MD PhD, Hassan Sibai, MBBS, Karen W.L. Yee, MD, Vikas Gupta, MD FRCP, FRCPath, Suzanne Kamel-Reid, BA, MA, PhD FACMG, Dawn Maze, MD FRCPC, MSc, Andre Schuh

Blood (2018) 132 (Supplement 1): 2666.

https://doi.org/10.1182/blood-2018-99-118938

Published: 2018

Journal Articles

Impact of Post-Hematopoietic Cell Transplant (HCT) Survival on Cost-Effectiveness of CPX-351 Versus 7+3 in the Treatment of Therapy-Related AML or AML-MRC in the United States

Anuraag Kansal, PhD, Odette Reifsnider, Lora Todorova, Anna Coughlan, Kathleen F. Villa

Blood (2018) 132 (Supplement 1): 5837.

https://doi.org/10.1182/blood-2018-99-112252

Published: 2018

Journal Articles

Efficacy and Safety of CPX-351 Versus 7+3 in a Subgroup of Older Patients with Newly Diagnosed Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Enrolled in a Phase 3 Study

Daniel H. Ryan, Geoffrey L. Uy, MD, Jorge E. Cortes, MD, Laura F. Newell, MD, Ellen K. Ritchie, MD, Robert K. Stuart, MD, Stephen A. Strickland, MD, Donna Hogge, Scott R Solomon, MD, Richard M. Stone, MD, Dale L. Bixby, MD PhD, Jonathan E. Kolitz, MD, Gary J. Schiller, MD, Matthew J. Wieduwilt, MD PhD, Robert Ryan, Michael Chiarella, Arthur C. Louie, Jeffrey E. Lancet, MD

Blood (2018) 132 (Supplement 1): 1425.

https://doi.org/10.1182/blood-2018-99-111514

Published: 2018

Journal Articles

No evidence that CD33 splicing SNP impacts the response to GO in younger adults with AML treated on UK MRC/NCRI trials

Rosemary E. Gale, Teodora Popa, Melissa Wright, Naeem Khan, Sylvie D. Freeman, Alan K. Burnett, Nigel H. Russell, Robert K. Hills, David C. Linch

Blood (2018) 131 (4): 468–471.

https://doi.org/10.1182/blood-2017-08-802157

Published: 2018

Includes: Supplemental data

Journal Articles

The Impact of Cytogenetic Clonality on Outcomes in Younger Acute Myeloid Leukemia Patients: Results on 1290 Patients Included in the EORTC/Gimema AML-10 and AML-12 Trials

Blood (2017) 130 (Supplement 1): 1385.

https://doi.org/10.1182/blood.V130.Suppl_1.1385.1385

Published: 2017

Journal Articles

Validation of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) Score for Hypomethylating Agents (HMAs) Use in Patients with Relapsed and Refractory Acute Myeloid Leukemia (RR-AML)

Blood (2017) 130 (Supplement 1): 3385.

https://doi.org/10.1182/blood.V130.Suppl_1.3385.3385

Published: 2017

Journal Articles

Survival Among Acute Myeloid Leukemia Patients Conditional on Years Already Survived and Relative to the General Population in the United States

Raffi Tchekmedyian, BS, Aziz Nazha, MD, Anjali S. Advani, MD, Aaron T. Gerds, MDMS, Hetty E. Carraway, MD MBA, Matt Kalaycio, MD, Jaroslaw P. Maciejewski, PhD MD FACP, Navneet S. Majhail, MD MS, Mikkael A. Sekeres, MD MS, Sudipto Mukherjee, MD PhD MPH

Blood (2017) 130 (Supplement 1): 344.

https://doi.org/10.1182/blood.V130.Suppl_1.344.344

Published: 2017

Journal Articles

Budget Impact Analysis of CPX-351 in the Treatment of Patients with Treatment-Related Acute Myeloid Leukemia (tAML) or AML with Myelodysplasia-Related Changes (MRC) from a US Payer Perspective

Ivar S Jensen, MBA, Elizabeth Wu, Naomi Sacks, Philip Cyr, MPH, Karen Chung

Blood (2017) 130 (Supplement 1): 5615.

https://doi.org/10.1182/blood.V130.Suppl_1.5615.5615

Published: 2017

Journal Articles

Cost-Effectiveness of CPX-351 Versus 7+3 Regimen in the Treatment of Treatment-Related Acute Myeloid Leukemia (tAML) or AML with Myelodysplasia-Related Changes (MRC)

Anuraag Kansal, Mark Du, Oscar Herrera-Restrepo, Robert Leipold, Robert J. Ryan, Arthur C. Louie, Karen Chung

Blood (2017) 130 (Supplement 1): 4674.

https://doi.org/10.1182/blood.V130.Suppl_1.4674.4674

Published: 2017

Journal Articles

Glia Maturation Factor-Gamma Modulates M2 Activation of Macrophage Via Suppression of Mitochondria Function

Wulin Aerbajinai, MD PhD, Jie Liu, Chutima Kumkhaek, Jianqiong Zhu, Kyung Chin, Griffin Rodgers, MD

Blood (2017) 130 (Supplement 1): 998.

https://doi.org/10.1182/blood.V130.Suppl_1.998.998

Published: 2017

NARROW

Outcome of Patients with Newly-Diagnosed Therapy-Related AML (t-AML) and AML with Myelodysplasia-Related Changes (AML-MRC) Treated with Liposomal Daunorubicin and Cytarabine (CPX-351) at an Academic Community-Based Health System

A Multicenter Nonrandom Clinical Study Using Induction Regimen of FLAG-IDA or Dae in Treatment of 101 Children with Newly Diagnosed CBF-AML in South of China: Clinical Responses and the Midterm Report of Survival

Phase 3 Exploratory Analysis of Outcomes in Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Received Consolidation with CPX-351 Versus Conventional Chemotherapy

Outcomes in Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory Analysis

Acute Myeloid Leukemia with Myelodisplasia-Related Changes (AML-MRC) Defined Only By Morphological Findings May Not Represent a Poor Prognosis AML

Molecular Classification of AML-MRC Reveals a Distinct Profile and Identifies MRC-like Patients with Poor Overall Survival

Outcomes of Patients with Acute Myeloid Leukemia (AML) with Myelodysplasia Related Changes (AML-MRC) Are Dependent on Diagnostic Criteria and Therapy

CPX-351 Induces Deep Response and Suppress the Impact of Poor Prognosis Mutations ( TP53, ASXL1, RUNX1 and EVI1 ) Defined By ELN-2017 in t-AML and MRC AML: A Report from a Multicentric French Cohort

Outcomes of Relapsed/Refractory Patients with IDH1/2 Mutated AML Treated with Non-Targeted Therapy: Results from the NCRI AML Trials

Comparison of Induction Strategies and Responses for Acute Myeloid Leukemia Patients after Resistance to Hypomethylating Agents for Antecedent Myeloid Malignancy

Impact of Genetic Profile on Clinical Outcomes in Adults ≥60 with AML: The Princess Margaret Cancer Centre Experience

Impact of Post-Hematopoietic Cell Transplant (HCT) Survival on Cost-Effectiveness of CPX-351 Versus 7+3 in the Treatment of Therapy-Related AML or AML-MRC in the United States

Efficacy and Safety of CPX-351 Versus 7+3 in a Subgroup of Older Patients with Newly Diagnosed Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Enrolled in a Phase 3 Study

No evidence that CD33 splicing SNP impacts the response to GO in younger adults with AML treated on UK MRC/NCRI trials

The Impact of Cytogenetic Clonality on Outcomes in Younger Acute Myeloid Leukemia Patients: Results on 1290 Patients Included in the EORTC/Gimema AML-10 and AML-12 Trials

Validation of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) Score for Hypomethylating Agents (HMAs) Use in Patients with Relapsed and Refractory Acute Myeloid Leukemia (RR-AML)

Survival Among Acute Myeloid Leukemia Patients Conditional on Years Already Survived and Relative to the General Population in the United States

Budget Impact Analysis of CPX-351 in the Treatment of Patients with Treatment-Related Acute Myeloid Leukemia (tAML) or AML with Myelodysplasia-Related Changes (MRC) from a US Payer Perspective

Cost-Effectiveness of CPX-351 Versus 7+3 Regimen in the Treatment of Treatment-Related Acute Myeloid Leukemia (tAML) or AML with Myelodysplasia-Related Changes (MRC)

Glia Maturation Factor-Gamma Modulates M2 Activation of Macrophage Via Suppression of Mitochondria Function

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only